Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H1 2018

  • ID: 4461756
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Asana BioSciences LLC
  • Johnson & Johnson
  • Novus Therapeutics Inc
  • MORE
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H1 2018

Summary:

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Steroid 17-alpha-hydroxylase/17, 20 lyase is an enzyme belonging to hydroxylase class that is encoded by CYP17A1 gene. It helps in conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. It catalyzes both the 17-alpha-hydroxylation and the 17, 20-lyase reaction. It is involved in sexual development during fetal life and at puberty.

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 2, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Breast Cancer, Metastatic Breast Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Metastatic Prostate Cancer, Peritoneal Cancer and Prostate Cancer.

The latest report Steroid 17 Alpha Hydroxylase17,20 Lyase - Pipeline Review, H1 2018, outlays comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from Report Coverageproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)
  • The report reviews Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics
Reasons to Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Asana BioSciences LLC
  • Johnson & Johnson
  • Novus Therapeutics Inc
  • MORE
Introduction

Report Coverage

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Overview

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Companies Involved in Therapeutics Development

Asana BioSciences LLC

Johnson & Johnson

Millennium Pharmaceuticals Inc

Novus Therapeutics Inc

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Drug Profiles

abiraterone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abiraterone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abiraterone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galeterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orteronel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seviteronel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP17 for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP17 Lyase for Breast Cancer and Castration Resistant Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Dormant Products

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Discontinued Products

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Product Development Milestones

Featured News & Press Releases

Jan 25, 2018: Janssen to Present data on ZYTIGA at Prostate and Urothelial Cancers at ASCO GU 2018

Jan 18, 2018: Amerigen's petition leads to U.S. Zytiga patent invalidation

Jan 17, 2018: Argentum Pharmaceuticals Wins Patent Invalidation Trial against the Sole Remaining Patent Protecting Janssens ZYTIGA

Jan 17, 2018: Johnson & Johnson Issues Statement on ZYTIGA Inter Partes Reviews

Dec 05, 2017: Moffitt Cancer Center Uses Innovative Treatment Strategy to Overcome Drug Resistance

Nov 22, 2017: European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer

Nov 20, 2017: European Commission Extends License for Janssen's ZYTIGA Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients

Oct 13, 2017: CHMP Issues a Positive Opinion on Janssen’s ZYTIGA to Include Earlier Stage Prostate Cancer Patients

Sep 14, 2017: Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer

Sep 08, 2017: New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer

Sep 08, 2017: Patients with high risk prostate cancer may benefit 'equally'from two new treatments

Jul 20, 2017: Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA by the U.S. FDA

Jul 19, 2017: Xian Janssen: ZYTIGA Included on the National Reimbursement Drug List 2017

Jun 20, 2017: Innocrin Pharmaceuticals Granted SME Status Designation by the European Medicines Agency

Jun 03, 2017: Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naive Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Asana BioSciences LLC, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Pipeline by Novus Therapeutics Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Asana BioSciences LLC
  • Johnson & Johnson
  • Millennium Pharmaceuticals Inc
  • Novus Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll